No Data
No Data
Sano Healthcare (688108.SH): Currently, the business mainly covers key areas of interventional treatment such as cardiovascular, cerebrovascular, and structural heart diseases
Gelonghui, May 10 | Sano Healthcare (688108.SH) said on the investor interactive platform that the company is an international company rooted in China, targeting the global market, and focusing on R&D, production and sales of high-end interventional medical devices. Currently, the company's business mainly covers key areas of interventional treatment such as cardiovascular, cerebrovascular, and structural heart diseases.
Sino Medical Sciences Technology Inc. (SHSE:688108) Surges 13%; Retail Investors Who Own 41% Shares Profited Along With Insiders
Key Insights Significant control over Sino Medical Sciences Technology by retail investors implies that the general public has more power to influence management and governance-related decisions The
Sano Healthcare (688108.SH) reported 2023 annual results with a net loss of 39.63 million yuan
Sano Healthcare (688108.SH) released its 2023 annual report. The company achieved operating income of 3 during the reporting period...
Sano Healthcare (688108.SH): Product obtained registration certificate in Belarus
On April 18, GLONGHUI (688108.SH) announced that in December 2023, the company submitted registration data for the company's HT SupremeTM drug-eluting stents, NCROCKSTARTM non-compliant balloon dilatation catheters, and SC HONKYTONKTM coronary balloon dilation catheters to the Ministry of Health of Belarus (“MOH” for short). The company recently received a notice from MOH, the company HT SupremeTM drug-eluting stents, NC ROCKSTART non-compliant balloon expansion catheter, SC HONK
Sano Healthcare (688108.SH): The company's products obtained a registration certificate in Korea
On March 15, GLONGHUI (688108.SH) announced that in November 2022 and May 2023, the company submitted registration data for the company's HTSUPremetM drug-eluting stent, NCROCKSTART non-compliant balloon dilatation catheter, and SCHONKYTONKTM coronary balloon dilation catheter to the Korean Ministry of Food and Drug Safety (hereinafter referred to as “MFDS”), respectively. The company recently received an MFDS notification that the company HTSUPremetM drug-eluting stents and NCROCKSTARTM non-compliant balloon dilatation
There's Reason For Concern Over Sino Medical Sciences Technology Inc.'s (SHSE:688108) Massive 41% Price Jump
Sino Medical Sciences Technology Inc. (SHSE:688108) shareholders are no doubt pleased to see that the share price has bounced 41% in the last month, although it is still struggling to make up recently
No Data